CVAC
CureVac NV
NASDAQ: CVAC · HEALTHCARE · BIOTECHNOLOGY
$4.66
+0.00% today
Updated 2026-04-30
Market cap
$1.05B
P/E ratio
6.96
P/S ratio
14.83x
EPS (TTM)
$0.67
Dividend yield
—
52W range
$3 – $6
Volume
1.1M
CureVac NV (CVAC) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $12.87M | $17.42M | $48.90M | $102.99M | $67.42M | $53.76M | $535.18M |
| Revenue growth (YoY) | — | +35.3% | +180.8% | +110.6% | -34.5% | -20.3% | +895.5% |
| Cost of revenue | $17.74M | $27.98M | $14.17M | $238.19M | $183.99M | $124.37M | $105.83M |
| Gross profit | $-4.87M | $-10.57M | $34.73M | $-135.21M | $-116.57M | $-70.61M | $429.35M |
| Gross margin | -37.9% | -60.7% | 71.0% | -131.3% | -172.9% | -131.3% | 80.2% |
| R&D | $41.72M | $43.24M | $113.81M | $815.91M | $62.55M | $115.72M | $153.03M |
| SG&A | $20.41M | $42.18M | $45.03M | $87.20M | $88.99M | $76.01M | $69.65M |
| Operating income | $-72.82M | $-99.50M | $-124.00M | $-412.26M | $-249.46M | $-274.21M | $177.68M |
| Operating margin | -565.8% | -571.3% | -253.6% | -400.3% | -370.0% | -510.1% | 33.2% |
| EBITDA | $-69.85M | $-93.90M | $-123.09M | $-386.49M | $-209.39M | $-234.09M | $209.69M |
| EBITDA margin | -542.7% | -539.2% | -251.7% | -375.3% | -310.6% | -435.5% | 39.2% |
| EBIT | $-73.74M | $-98.67M | $-136.71M | $-422.36M | $-235.55M | $-257.48M | $190.88M |
| Interest expense | $275000.00 | $1.46M | $22.10M | $10.34M | $3.71M | $2.49M | $0.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-71.24M | $-99.87M | $-129.07M | $-411.72M | $-249.03M | $-260.17M | $162.19M |
| Net income growth (YoY) | — | -40.2% | -29.2% | -219.0% | +39.5% | -4.5% | +162.3% |
| Profit margin | -553.5% | -573.5% | -264.0% | -399.8% | -369.4% | -484.0% | 30.3% |